EU Aims for Tougher Scrutiny of Silicon Valley Data-Heavy Deals

Advertisement
By Gaspard Sebag, Bloomberg | Updated: 7 October 2016 18:14 IST

The European Union may include purchase prices in the criteria used to trigger its antitrust probes, aiming to catch more data-heavy transactions in serious merger reviews in another warning shot to Silicon Valley.

The European Commission said Friday the EU's revenue-based rules mean some deals can currently avoid scrutiny when the target company doesn't have significant sales even if it "already plays a competitive role, holds commercially valuable data, or has a considerable market potential for other reasons."

Advertisement

EU antitrust chief Margrethe Vestager, who took office at the end of 2014, has signaled a willingness to delve more into how merging companies leverage the trove of data at their disposal. Data was one of the key considerations in the review of Facebook Inc.'s takeover of messaging service WhatsApp Inc. While the EU cleared it in October 2014, Vestager said last month officials were now "asking some follow-up questions" about privacy-policy changes.

Vestager signalled in June that Microsoft Corp.'s acquisition of professional social network LinkedIn Corp. is another deal where any EU probe would likely focus on its potential to leverage vast amounts of user data.

Advertisement

"Players in the digital economy may have considerable actual or potential market impact that may be reflected in high acquisition values, although they may not yet generate any or only little turnover," the EU said Friday as it sought feedback on possible changes. "It has been suggested to complement the existing turnover-based jurisdictional thresholds of the EU merger regulation by additional notification requirements based on alternative criteria, such as the transaction value."

The EU considers the possible legal gap may also affect the pharmaceutical industry.

Advertisement

"There have been indeed a number of highly valued acquisitions, by major pharmaceutical companies, of small biotechnology companies, which predominantly research and develop new treatments that may have high commercial potential, and do not yet generate any or only little turnover," the commission said.

© 2016 Bloomberg L.P.

 

Get your daily dose of tech news, reviews, and insights, in under 80 characters on Gadgets 360 Turbo. Connect with fellow tech lovers on our Forum. Follow us on X, Facebook, WhatsApp, Threads and Google News for instant updates. Catch all the action on our YouTube channel.

Further reading: EU, Facebook, WhatsApp, Margrethe Vestager
Advertisement

Related Stories

Popular Mobile Brands
  1. Xiaomi 18 Pro vs iPhone 18 Pro vs Pixel 11 Pro: What's the Difference
  1. Logitech MX Master 4 Creator Edition With Customisable Controls, Haptic Feedback Launched in India: Price, Features
  2. SEC Takes Action Against Eight Entities in $37 Million Crypto Fraud Case
  3. Galaxy Z Fold 9, Z Fold 9 Ultra Hit IMEI Database as Samsung Preps Next Foldables
  4. Indian Crypto Exchanges Report INR Withdrawal Disruptions Across Platforms
  5. Samsung’s Googlebooks Codenamed ‘Origin’ Show Up in Leaked One UI 9.5 Beta Code
  6. Nothing’s First Screenless AI Device Launches December 8: Design Teased
  7. Vivo V80 FE Could Launch in India in Exclusive Red Colour Option, Tipster Claims
  8. Apple is Reportedly Developing AI Agent for App Control, Web Browsing and Coding
  9. Google Black Friday 2026 Sale Live: Save Up to $600 on Pixel 11, Pixel Watch 5
  10. Dell XPS 16 Creator Edition Laptop With Nvidia RTX Spark N1X Processor Launched in India: Price, Specifications
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2026. All rights reserved.